Results 241 to 250 of about 48,818 (277)
Some of the next articles are maybe not open access.
ESTROGENS AND POSTMENOPAUSAL OSTEOPOROSIS
Clinical Obstetrics and Gynecology, 1976A model for the development of osteoporosis is presented and the tre atment of the condition with estrogens is discussed. It appears that an age-related reduction in circulating estrogens accompanies menopausal bone loss. However this loss is more directly attributable to the lack of parathyroid hormone (PTH) while estrogens play a role in the bony ...
openaire +2 more sources
Calcitriol for Postmenopausal Osteoporosis
Annals of Internal Medicine, 1990Excerpt To the Editor:Gallagher and Riggs (1) recently criticized the report by Ott and Chesnut (2) on calcitriol treatment in postmenopausal osteoporosis.
openaire +2 more sources
Treatment of Postmenopausal Osteoporosis
New England Journal of Medicine, 1998Osteoporosis affects an estimated 75 million people in Europe, the United States, and Japan.1 It is a preventable and treatable condition, yet many people with osteoporosis remain unrecognized and untreated. The purpose of this review is to consider the evidence that treatments for postmenopausal osteoporosis are effective and safe.
openaire +2 more sources
Treatment of Postmenopausal Osteoporosis
Annals of Internal Medicine, 1987Excerpt To the editor: In their recent article, Ettinger and colleagues (1) state that 9.0% of untreated women with postmenopausal osteoporosis and 10.5% of women given calcium supplements had mean...
openaire +2 more sources
Pathogenesis of postmenopausal osteoporosis
Baillière's Clinical Rheumatology, 1993Osteoporosis is a disorder of ageing that shares with other disorders of ageing a multifactorial pathogenesis. The important factors for osteoporosis include the diet, life-style and intercurrent factors such as disease. However, it is clear that loss of ovarian function is an important determinant of bone loss, and oestrogen appears to be the key ...
openaire +2 more sources
Treatment of postmenopausal osteoporosis
The Lancet, 2002The aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease. Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1-34 fragment of parathyroid hormone, and ...
openaire +2 more sources
Interaction between bone and immune cells: Implications for postmenopausal osteoporosis
Seminars in Cell and Developmental Biology, 2022Verena Fischer +1 more
exaly